Literature DB >> 20808237

In vivo differentiation of magnetically labeled mesenchymal stem cells into hepatocytes for cell therapy to repair damaged liver.

Shenghong Ju1, Gao-Jun Teng, Haihua Lu, JiYang Jin, Yu Zhang, Aifeng Zhang, Yicheng Ni.   

Abstract

OBJECTIVES: It was unclear whether systemically administered mesenchymal stem cells (MSCs) labeled with magnetic nanoparticles can transdifferentiate into hepatocytes. In the present study, we built a new in vivo murine model for monitoring the transdifferentiation of magnetically labeled green fluorescent protein (GFP) positive MSCs into albumin-positive hepatocytes, under the carbon tetrachloride (CCl4) induced persistent liver damage. We also tracked magnetically labeled MSCs by using magnetic resonance imaging (MRI) in vivo.
MATERIALS AND METHODS: Among the liver damage groups, magnetically labeled GFP-positive MSCs (group A), GFP-positive MSCs (group B), and saline alone (group C) were intravenously injected. In control groups without CCl4 administration magnetically labeled GFP-positive MSCs (group D) were infused, whereas nothing was given in group E. MRI examinations were performed 24 hours and 4 weeks after cell injection in group A, B, and C. Liver-to-muscle contrast-to-noise ratios on T2*-weighted MR images were measured. At 4 weeks, 3 serum biologic liver function markers were analyzed, and mice in all groups were killed for histologic examination.
RESULTS: The results showed that migration of transplanted magnetic labeled cells to the liver was successfully documented with in vivo MRI. Serum liver function markers were changed for all liver damage groups than nondamage control groups (P < 0.05), but still insignificant compared with group C (P > 0.05). Hematoxylin and eosin and Masson staining confirmed the presence of liver damage and hepatic fibrosis in group A, B, and C. Positive Prussian blue stained cells were highly correlated with GFP-positive cells in group A with an average matching rate of 95%. In group D, no iron-GFP-positive cells can be found in the liver. Albumin was expressed in (34% ± 6%) and (35% ± 7%) of GFP-positive cells in group A and B, respectively, and there was no significant difference between the 2 groups.
CONCLUSIONS: Our data demonstrate that magnetic labeling technique synchronized well in GFP expressing MSCs and did not interfere with the transdifferentiation process and amending function of MSCs in vivo. Both magnetically labeled and unlabeled MSCs appeared to have the potential to differentiate into hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20808237     DOI: 10.1097/RLI.0b013e3181ed55f4

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  13 in total

Review 1.  Role of mesenchymal stem cells in leukaemia: Dr. Jekyll or Mr. Hyde?

Authors:  Rebecca S Y Wong; Soon-Keng Cheong
Journal:  Clin Exp Med       Date:  2013-06-23       Impact factor: 3.984

2.  Promoting the recovery of injured liver with poly (3-hydroxybutyrate-co-3-hydroxyvalerate-co-3-hydroxyhexanoate) scaffolds loaded with umbilical cord-derived mesenchymal stem cells.

Authors:  Pengshan Li; Jin Zhang; Jing Liu; Huan Ma; Jie Liu; Puchang Lie; Yuechun Wang; Gexiu Liu; Huilan Zeng; Zhizhong Li; Xing Wei
Journal:  Tissue Eng Part A       Date:  2014-11-14       Impact factor: 3.845

3.  Labeling and tracing of bone marrow mesenchymal stem cells for tendon-to-bone tunnel healing.

Authors:  Yong-Gang Li; Ji-Nan Wei; Jun Lu; Xiao-Tao Wu; Gao-Jun Teng
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2011-04-19       Impact factor: 4.342

Review 4.  Mesenchymal stem cells: angels or demons?

Authors:  Rebecca S Y Wong
Journal:  J Biomed Biotechnol       Date:  2011-07-24

Review 5.  Molecular Imaging of Stem Cell Transplantation for Liver Diseases: Monitoring, Clinical Translation, and Theranostics.

Authors:  Ping Wang; Francesco Petrella; Luca Nicosia; Massimo Bellomi; Stefania Rizzo
Journal:  Stem Cells Int       Date:  2016-12-14       Impact factor: 5.443

6.  In vivo hepatic differentiation potential of human umbilical cord-derived mesenchymal stem cells: Therapeutic effect on liver fibrosis/cirrhosis.

Authors:  Guo-Zun Zhang; Hui-Cong Sun; Li-Bo Zheng; Jin-Bo Guo; Xiao-Lan Zhang
Journal:  World J Gastroenterol       Date:  2017-12-14       Impact factor: 5.742

7.  Effect of CXCR3/HO-1 genes modified bone marrow mesenchymal stem cells on small bowel transplant rejection.

Authors:  Ming-Li Yin; Hong-Li Song; Yang Yang; Wei-Ping Zheng; Tao Liu; Zhong-Yang Shen
Journal:  World J Gastroenterol       Date:  2017-06-14       Impact factor: 5.742

8.  Transplantation of mesenchymal stem cells in a laryngeal carcinoma patient with radiation myelitis.

Authors:  Jun Liang; Fan Wang; Dandan Wang; Huayong Zhang; Cheng Zhao; Shiying Wang; Lingyun Sun
Journal:  Stem Cell Res Ther       Date:  2015-11-04       Impact factor: 6.832

9.  Highly efficient mesenchymal stem cell proliferation on poly-ε-caprolactone nanofibers with embedded magnetic nanoparticles.

Authors:  Jana Daňková; Matej Buzgo; Jana Vejpravová; Simona Kubíčková; Věra Sovková; Lucie Vysloužilová; Alice Mantlíková; Alois Nečas; Evžen Amler
Journal:  Int J Nanomedicine       Date:  2015-12-07

10.  Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis.

Authors:  Huayong Zhang; Jun Liang; Xiaojun Tang; Dandan Wang; Xuebing Feng; Fan Wang; Bingzhu Hua; Hong Wang; Lingyun Sun
Journal:  Arthritis Res Ther       Date:  2017-07-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.